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Until the advent of Magnetic Resonance
Imaging (MRI), diagnosis of MS was very
difficult and several cases of misdiagnosis
are recorded. In a study of MS in Malta
carried out in 1978 by Drs Dean and Elian,
14 persons with MS were identified. A
second survey in 1999 by the same doctors,
in conjunction with Maltese consultant
neurologists, showed a significant increase
but the prevalence in Malta remains very
low. According to the records of the Multiple
Sclerosis Society of Malta the current
number of confirmed cases hovers around
the figure of 100
As yet there is neither a cure for, nor a
certainty as to the causes of MS which is an
inflammatory demyelinating condition in
which the myelin is attacked by the body’s
immune system itself.   Myelin, the fatty
substance insulating the nerve fibres,
ensures that messages from the brain are
transmitted speedily and efficiently to the
rest of the body.   In MS, the loss of myelin
causes a disruption in the ability of nerves
to conduct electrical impulses to and from
the brain with the result that the different
parts of the body fail to react to stimuli
from the brain. The sites where myelin is
lost appear as hardened scar areas (plaques)
and they appear at different times and in
different areas of the brain and spinal cord.
Researchers do not know what triggers the
immune system to attack myelin; one theory
is that a dormant virus in the body (e.g.
measles or herpes) may act as a trigger by
activating the white blood cells, which
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enter the brain by rendering vulnerable the
brain’s defence mechanisms. Once inside the
brain these cells activate other elements of
the immune system in such a way that they
attack and destroy myelin. The most
common symptoms of MS are blurred vision,
numbness or tingling of the limbs, fatigue
and problems with coordination. There are
four types of MS: relapsing – remitting
(25%); secondary (20%); progressive
(approx. 40%) and primary progressive
(15%). The course of MS is unpredictable.
Some people are minimally affected while
others have rapid progress to total
disability, with most people fitting between
the two extremes.
There is considerable research all over
the world about causes of and cures for MS.
In their report following the 1999 survey,
Dean and Elian suggested that the reason
for the low prevalence of MS in Malta could
be explained by environmental factors and,
more importantly, by a different genetic
make up of the Maltese people to the rest of
Europe. Indeed, Dean and Elian suggest that
Malta offers a unique opportunity for
researchers to ascertain the relative
importance of genetic and environmental
factors responsible for MS.
Researchers come up with possible cures
on a regular basis; goat serum, statins and
cannabis have been indicated in recent
months. More recently a major milestone
was reached through the identification of
80 genes involved in MS.  This is a
significant step forward in building a
complete inventory of genes involved in MS.
The completion in 2006 of the MS Whole
Genome Scan will lead to a comprehensive
catalogue of potential MS drug targets, thus
providing the basis for the future development
of innovative MS therapies.  The
understanding of the disease’s genetics will
enhance the possibility of identifying proteins
that can be used either as targets for drug
development or directly as therapeutics. In
addition, the knowledge of genetics in MS
provides a basis for the better designing of
safer and more effective drugs and for
enabling physicians to address unmet needs
and potentially match treatments to individual
patients.
In Malta, the Multiple Sclerosis Society
was set up in October 1997 at a meeting at
St. Philip’s hospital. The Society organizes
monthly meetings for its members and their
families and organizes a number of social
events so that members have the chance to
interact.  Several members are wheelchair
bound and have very limited opportunities for
socializing.   The Society provides
physiotherapy services held at home at a
subsidized rate; this service has proved very
useful and there is increasing demand for it.
Equally successful and popular are the group
psychotherapy sessions held at the Hospice
Movement, which has become the Society’s
regular meeting place. Ideally, the Society
wishes to offer psychotherapy on an individual
basis but its limited funds preclude it from
embarking on this step as yet. The Society
constantly offers advice to members, visits
members who are house-bound, and acts as a
lobby with government. It is very active on
the international front with a seat on the
Executive Committee of the MS International
Federation and a very active participation in
the activities of the European MS Platform
(EMSP).  The 2003 EMSP annual congress was
held in Malta and the Maltese association is
regularly invited to participate in seminars
and workshops of the Platform. Last year EMSP
provided the services of a Polish volunteer for
a whole year to instruct members of the
society on how to use computers.
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